ClinicalTrials.gg
CompletedNCT06277934Updated Aug 7, 2025

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

A Phase 2 interventional study of RGT001-075 and Placebo in Obesity, sponsored by Regor Pharmaceuticals Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Regor Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

This study's enrollment of 73 is close to the median of 67 across 9,027 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Regor Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 and ≤ 75 years
  • Have a ≥27 kg/m² and ≤ 45 kg/m²
  • Have had a stable body weight for the 3 months prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity
  • Have a prior or planned surgical treatment for obesity
  • Have or plan to have endoscopic and/or device-based therapy for obesity
  • Have any prior diagnosis of diabetes
  • Have an (ECG) with abnormalities
  • Have a history of Major Depressive Disorder (MDD) or other severe psychiatric disorders within the last 2 years
  • Have a history of suicide attempt.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    RGT001-075 Group

    Patients will receive once daily dose of study drug for a total of 12 weeks

    Drug: RGT001-075

  • Placebo comparator
    Placebo Group

    Patients will receive once daily dose of matching placebo for a total of 12 weeks

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-emergent Adverse Event(AE) by severity/Serious Adverse Event (SAE), with Clinical Laboratory Abnormalities, Clinically Significant Change From Baseline in Vital Signs and Abnormal Electrocardiogram(ECG) readings

    Time frame: 14 weeks

Secondary outcomes

  1. Percent change in body weight

    Percent change in body weight from baseline at Week 12

    Time frame: 12 weeks

  2. Change in body weight in kilogram

    Change in body weight from baseline at Week 12

    Time frame: 12 weeks

  3. Percentage of participants who achieve ≥5% and ≥10% body weight reduction

    Percentage of participants who achieve ≥5% and ≥10% body weight reduction at Week 12

    Time frame: 12 weeks

  4. Change in Body mass index (BMI) in kg/m^2

    Change in BMI from baseline at Week 12

    Time frame: 12 weeks

  5. Change in waist circumference in centimetre

    Change in waist circumference from baseline at Week 12 .

    Time frame: 12 weeks

  6. RGT001-075 pharmacokinetics (PK): Area under the curve up to the last measured concentration(AUC0-last)

    Analysis of AUC0-last

    Time frame: 12 weeks

  7. RGT001-075 pharmacokinetics (PK): Area under curve from time zero to time infinite(AUC0-inf)

    Analysis of AUC0-inf

    Time frame: 12 weeks

  8. RGT001-075 pharmacokinetics (PK): Maximum observed concentration (Cmax)

    Analysis of Cmax

    Time frame: 12 weeks

  9. RGT001-075 pharmacokinetics (PK): Time to achieve maximum concentration(Tmax)

    Analysis of Tmax

    Time frame: 12 weeks

  10. RGT001-075 pharmacokinetics (PK): Elimination half-life(t1/2)

    Analysis of t1/2

    Time frame: 12 weeks

07

Study locations

10 sites
  • Velocity Clinical Research
    Los Angeles, California 90057, United States
  • Velocity Clinical Research
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research
    Vestal, New York 13850, United States
  • Velocity Clinical Research
    Durham, North Carolina 27701, United States
  • Velocity Clinical Research
    Cleveland, Ohio 44122, United States
  • Velocity Clinical Research
    Medford, Oregon 97504, United States
  • Velocity Clinical Research
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research
    Dallas, Texas 75230, United States
  • Velocity Clinical Research
    West Jordan, Utah 84088, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2024, 5 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 5 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 26, 2024
StartActual
Mar 8, 2024
Primary completionActual
Aug 13, 2024
CompletionActual
Aug 13, 2024
Results delay requested
Aug 4, 2025
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06277934
Lead sponsor
Regor Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Mar 8, 2024
Primary completion
Aug 13, 2024
Completion
Aug 13, 2024
Last update
Aug 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RGT001-075

Start the discussion